| CAT # | Product Name | Description |
| CPD2047 | VK2809 | |
| CPD2053 | MB-07811 | MB-07811, also known as MB-07344, is a thyroid hormone receptor beta (TRB) agonist potentially for the treatment of hyperlipidemia. The prodrug [MB07811] of a novel phosphonate-containing thyroid hormone receptor agonist [MB07344] is the first application of the HepDirect liver-targeting approach to a non-nucleotide agent. |
| CPD2040 | BMS-986195 R-isomer | |
| CPD0201 | BI1744-HCl | BI1744 is a long acting β2-adrenoceptor agonist with an EC50 of 1.4±0.08 nM. |
| CPD2050 | PCO371 | Parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor (PTHR1), a class B G-protein-coupled receptor. Hypoparathyroidism and osteoporosis can be treated with PTH injections; however, no orally effective PTH analogue is available. |
| CPD2051 | Baloxavir | Baloxavir is an anti-influenza agent extracted from patent WO 2017104691 A1. |
| CPDD1122 | Mirogabalin besylate | Mirogabalin, also known as DS-5565, is an α2δ-1 ligand being developed for pain associated with diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia. It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain. |
| CPD2046 | Resmetirom | Resmetirom, or MGL-3196, shows outstanding safety in a rat heart model and is efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. |
| CPDD1578 | CU-CPT-8m | |
| CPDD2004 | CU-CPT-9b | |
| CPDD1577 | CU-CPT-9a | |
| CPDD2044 | Vardenafil | Vardenafil, also known as BAY 38-9456, is a PDE5 inhibitor used for treating erectile dysfunction. |
| CPDD2043 | Etoricoxib | Etoricoxib is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. |
| CPDD2041 | Sildenafil Citrate | Sildenafil, Citrate is a citrate form of Sildenafil. Sildenafil is a selective inhibitor of PDE5 (type 5 cGMP phosphodiesterase) which catalyzes the hydrolysis of 3',5'-cyclic guanosine monophosphate (cGMP). |
| CPDD1640 | BMS-986195 | BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in antigen-dependent B-cell signaling and function. |
| CPD1562 | PZM-21 | PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM. |
| CPDD1644 | PRN1008 | PRN1008 is a potent, selective and reversible covalent inhibitor of BTK ((IC50 = 1.3 ± 0.5 nM).) with extended PD effects in vivo. |
| CPDD1626 | AZD-7594 | AZD-7594, also known as AZ13189620, is an inhaled selective glucocorticoid receptor (GCCR) modulator. |
| CPDD0995 | Bardoxolone methyl | The synthetic oleanane triterpenoid CDDO (Item No. 81035) is a Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells. |
| CPD1549 | Tropifexor | Tropifexor is a novel and highly potent agonist of FXR with an EC50 of 0.2 nM. |
| CPDB3744 | Ozanimod | Ozanimod (RPC1063) is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC). |
| CPD1017 | Bardoxolone | Bardoxolone is a novel nuclear regulator factor (Nrf-2) activator. |
| CPD1122 | Mirogabalin | Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium channel complexes in the CNS. |
| CPDD1550 | GW-870086 | GW-870086 is a glucocorticoid receptor agonist potentially for the treatment of asthma and atopic dermatitis. |
